Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study

Mubashra Butt, Adliah Mhd Ali, Mohd Makmor Bakry, Norlaila Mustafa, Mubashra Butt, Adliah Mhd Ali, Mohd Makmor Bakry, Norlaila Mustafa

Abstract

Malaysia is situated in Western Pacific region which bears 36.17% of total diabetes mellitus population. Pharmacist led diabetes interventions have been shown to improve the clinical outcomes amongst diabetes patients in various parts of the world. Despite high prevalence of disease in this region there is a lack of reported intervention outcomes from this region. The aim of this study was to evaluate the impact of a pharmacist led intervention on HbA1c, medication adherence, quality of life and other secondary outcomes amongst type 2 diabetes patients.

Method: Type 2 diabetes mellitus patients (n = 73) attending endocrine clinic at Universiti Kebangsaan Malaysia Medical Centre (UKMMC) were randomised to either control (n = 36) or intervention group (n = 37) after screening. Patients in the intervention group received an intervention from a pharmacist during the enrolment, after three and six months of the enrolment. Outcome measures such as HbA1c, BMI, lipid profile, Morisky scores and quality of life (QoL) scores were assessed at the enrolment and after 6 months of the study in both groups. Patients in the control group did not undergo intervention or educational module other than the standard care at UKMMC.

Results: HbA1c values reduced significantly from 9.66% to 8.47% (P = 0.001) in the intervention group. However, no significant changes were noted in the control group (9.64-9.26%, P = 0.14). BMI values showed significant reduction in the intervention group (29.34-28.92 kg/m(2); P = 0.03) and lipid profiles were unchanged in both groups. Morisky adherence scores significantly increased from 5.83 to 6.77 (P = 0.02) in the intervention group; however, no significant change was observed in the control group (5.95-5.98, P = 0.85). QoL profiles produced mixed results.

Conclusion: This randomised controlled study provides evidence about favourable impact of a pharmacist led diabetes intervention programme on HbA1c, medication adherence and QoL scores amongst type 2 diabetes patients at UKMMC, Malaysia.

Keywords: Diabetes management; Diabetes mellitus; HbA1c; Intervention; Medication adherence; Pharmacist; Quality of life.

Figures

Figure 1
Figure 1
Trial flow diagram in accordance with CONSORT guidelines (CONSORT, Consolidated Standards of Reporting Trials).
Figure 2
Figure 2
(a) Mean baseline and final HbA1c values in control and intervention groups and (b) mean change in HbA1c values during study duration.

References

    1. Al Mazroui N.R., Kamal M.M. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. Br. J. Clin. Pharmacol. 2009;67(5):547–557.
    1. Alhabib S., Aldraimly M. An evolving role of clinical pharmacists in managing diabetes: evidence from the literature. Saudi Pharm. J. 2014
    1. Al-Qazaz H.K., Hassali M.A. The eight-item Morisky medication adherence scale MMAS: translation and validation of the Malaysian version. Diabetes Res. Clin. Practice. 2010;90(2):216–221.
    1. Association A.D. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):s74–s77.
    1. Association A.D. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):s68–s71.
    1. Association A.D. Standards of medical care in diabetes. Diabetes Care. 2013;36(Suppl 1):S11–S66.
    1. Borges A.P.d.S., Guidoni C.M. The pharmaceutical care of patients with type 2 diabetes mellitus. Pharm. World Sci. 2010;32(6):730–736.
    1. Chan J.C.N., Malik V. Diabetes in Asia; epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–2140.
    1. Choe H.M., Mitrovich S. Proactive case management of high-risk patients with Type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am. J. Manage. Care. 2005;11:253–260.
    1. Collins C., Limone B.L. Effect of pharmacist intervention on glycemic control in diabetes. Diabetes Res. Clin. Practice. 2011;92(2):145–152.
    1. International Diabetes Federation. 2013. IDF Diabetes Atlas, sixth ed. International Diabetes Federation, Brussels, Belgium <>.
    1. Jarab A.S., Alqudah S.G. Randomized controlled trial of clinical pharmacy management of patients with Type 2 diabetes in an outpatient diabetes clinic in Jordan. J. Manage. Care Pharm. 2012;18:516–526.
    1. Johnson C.L., Nicholas A. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. J. Am. Pharm. Assoc. 2008;48:722–730.
    1. Kelly C., Rodgers P.T. Implementation and evaluation of a pharmacist-managed diabetes service. J. Manage. Care Pharm. 2000;6:488–493.
    1. Lanting L.C.J., Inez M.A., Mackenbach J.P. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients; a review. Diabetes Care. 2005;28(9):2280–2288.
    1. Lim P.C., Lim K. Evaluation of a pharmacist-managed diabetes medication therapy adherence clinic. Pharm. Practice. 2010;8(4):250–254.
    1. Ma R.C.W., Chan J.C.N. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann. N.Y Acad. Sci. 2013;1281:64–91.
    1. Malaysian Ministry of Health. 2013. Management of Type 2 diabetes mellitus <> (Last accessed on May 2013).
    1. McCord A.D. Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy. 2006;26:248–253.
    1. McWhorter L., GM O. Providing diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25:96–109.
    1. Mehuys E., Van Bortel L. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial. J. Clin. Pharm. Ther. 2011;36(5):602–613.
    1. Mitchell B., Armoura C. Diabetes medication assistance service: the pharmacist’s role in supporting patient self-management of type 2 diabetes (T2DM) in Australia. Patient Educ. Counselling. 2011;83(3):288–294.
    1. Odegard P.S., Goo A. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann. Pharmacother. 2005;39(3):433–440.
    1. Oyetayo O.O., James C. The Hispanic diabetes management program: impact of community pharmacists on clinical outcomes. J. Am. Pharm. Assoc. 2011;51(5):623–626.
    1. Phumipamorn S., Pongwecharak J. Effects of the pharmacist’s input on glycaemic control and cardiovascular risks in Muslim diabetes. Prim Care Diabetes. 2008;2(1):31–37.
    1. Ragucci K.R., Fermo J.D. Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005;25(12):1809–1816.
    1. Roglic G., Unwin N. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130–2135.
    1. Rothman R., Malone R. Pharmacist-led, primary care-based disease management improves hemoglobin A1c in high-risk patients with diabetes. Am. J. Med. Qual. 2003;18(2):51–58.
    1. Sarkadi A., Rosenqvist U. Experience-based group education in type 2 diabetes: a randomised controlled trial. Patient Educ. Counselling. 2004;53:291–298.
    1. Scott D.M., Boyd S.T. Outcomes of pharmacist-managed diabetes care services in a community health center. Am. J. Health Syst. Pharm. 2006;63(21):2116–2122.
    1. Wild S., Roglic G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir